Los Angeles, CA – June 22, 2026 – Researchers at the Terasaki Institute for Biomedical Innovation have developed an injectable hydrogel, a water-based gel material, made from silk proteins and a plant-derived compound. In laboratory tests, the material promoted complete wound closure within 72 hours, suggesting a potential new approach to minimally invasive soft tissue repair.
Los Angeles, CA – June 15, 2026 – Researchers from the Terasaki Institute for Biomedical Innovation together with key pioneers in glioma biology, neuro-oncology, and stem cell biology, have published a comprehensive review in Society for Neuro-Oncology’s journal Neuro-Oncology outlining the evolving landscape of glioma organoid technologies and proposing a foundational classification framework to guide translational brain tumor research.
Los Angeles, CA – June 4, 2026 – Researchers at the Terasaki Institute for Biomedical Innovation and University of Arizona College of Medicine, have developed a topical gel formulation with 4-aminopyridine (4-AP) - to treat burn wounds, achieving near-complete closure in 21 days. The findings are published in the journal Biomaterials.
Los Angeles, CA — April 21, 2026 — The Terasaki Institute for Biomedical Innovation invites the public to its 2026 Open House on Saturday, April 25, from 10:00 AM to 2:00 PM. Free and open to all ages, the event offers a rare behind-the-scenes and witness firsthand how cutting-edge science is being translated into real-world healthcare solutions.
Los Angeles, CA — April 8, 2026 — The Terasaki Institute for Biomedical Innovation (TIBI) is proud to announce that Principal Investigator Dr. Yangzhi Zhu has published their research in Science Translational Medicine, marking a major milestone for the institute.
Los Angeles, CA — March 30, 2026 — The Terasaki Institute for Biomedical Innovation is proud to announce that Dr. Yangzhi Zhu has been received a prestigious Career Development Award from the American Heart Association (AHA). The award will provide a total of $231,000 over three years to support his research in translational biosensing and organ health assessment.
Los Angeles, CA — March 19, 2026 — The Terasaki Institute for Biomedical Innovation (TIBI) and UCLA Technology Development Group (TDG) announced today a collaboration to program the Advanced Organ and Tissue Repair session during MedTech Day at LABEST, one of Southern California’s premier innovation conferences.
Los Angeles, CA — March 17, 2026 — The Terasaki Institute for Biomedical Innovation (TIBI) is proud to announce that Principal Investigator Dr. Aliesha O’Raw, Co-Founder of OnVagus, has been selected for the 2026 American Cancer Society (ACS) BrightEdge Entrepreneurs (BEE) Program cohort. The BrightEdge Entrepreneurs Program is a competitive program for startups in the cancer diagnostic and therapeutic space, providing mentorship and entrepreneur training alongside early-stage investment support, including a $100,000 SAFE (Simple Agreement for Future Equity) backed by ACS’ BrightEdge Investment Fund.